Central nervous system disorders

H1 2021 Neuromyelitis Optica (Devic's Syndrome) Global Clinical Trials Review - ResearchAndMarkets.com

Retrieved on: 
Friday, June 18, 2021
Biotechnology, Other Health, Health, Pharmaceutical, Clinical trials, Neurological disorders, Health sciences, Health, Autoimmune diseases, Devic, Central nervous system disorders, Clinical trial, Neuromyelitis optica spectrum disorder, Myelitis, NMO

The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Neuromyelitis Optica (Devic's Syndrome) - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report provides an overview of Neuromyelitis Optica (Devic's Syndrome) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Neuromyelitis Optica (Devic's Syndrome) .
  • Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe.

Aeterna Zentaris Engages Dr. Michael Levy to Support Development of Autoimmune and Inflammatory CNS Disorders Programs

Retrieved on: 
Monday, June 7, 2021
Neurological disorders, Autoimmune diseases, Central nervous system, Nervous system, Rare diseases, Neuromyelitis optica spectrum disorder, Central nervous system disorders, Myelitis

Dr. Levy will provide scientific support and advice to Aeterna Zentaris in the field of inflammatory CNS disorders, autoimmune diseases of the nervous system, and NMOSD.

Key Points: 
  • Dr. Levy will provide scientific support and advice to Aeterna Zentaris in the field of inflammatory CNS disorders, autoimmune diseases of the nervous system, and NMOSD.
  • We are pleased to welcome Dr. Levy and to have his support as we advance the development of this important program forward, commented Dr. Klaus Paulini , Chief Executive Officer of Aeterna.
  • I am excited to support Aeterna Zentaris development of AIM Biologicals and to potentially offer a new treatment for NMOSD patients, where there remains significant unmet medical need.
  • Dr. Levy is also an Associate Professor at Harvard Medical School and Director of the Neuromyelitis Optica Clinic and Research Laboratory at MGH.

New Analysis of UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD) Published in Neurology Neuroimmunology & Neuroinflammation

Retrieved on: 
Thursday, May 6, 2021
Biotechnology, Pharmaceutical, Health, Clinical trials, Branches of biology, Medical specialties, Clinical medicine, Autoimmune diseases, Rare diseases, Neurology, Central nervous system disorders, Neuromyelitis optica spectrum disorder, Multiple sclerosis, Myelitis, Neuroimmunology, Inebilizumab, UPLIZNA, Neuromyelitis Optica Spectrum Disorder (NMOSD), Horizon, UPLIZNA, NEUROMYELITIS OPTICA SPECTRUM DISORDER (NMOSD), HORIZON

These data are published in the May issue of Neurology Neuroimmunology & Neuroinflammation.

Key Points: 
  • These data are published in the May issue of Neurology Neuroimmunology & Neuroinflammation.
  • Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
  • Available at: https://nn.neurology.org/content/8/3/e978 .\nSerum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker.
  • Review: Recent advances in the understanding of the pathophysiology of neuromyelitis optica spectrum disorder.

CHMP Recommends EU Approval of Chugai’s Enspryng (Satralizumab) for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Retrieved on: 
Monday, April 26, 2021
Biotechnology, Health, Pharmaceutical, Optical, Clinical trials, Autoimmune diseases, Neurological disorders, Clinical medicine, Medicine, Multiple sclerosis, Rare diseases, Central nervous system disorders, Neuromyelitis optica spectrum disorder, Myelitis, NMO, MOG antibody disease, Inflammatory demyelinating diseases of the central nervous system

Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability.

Key Points: 
  • Patients with NMOSD frequently experience a relapsing disease course with repeated attacks leading to accumulating neurological damage and disability.
  • Neuromyelitis optica spectrum disorder (NMOSD) Online.
  • Lin J, Li X, Xia J. Th17 cells in neuromyelitis optica spectrum disorder: a review.
  • International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Study: Black People May Respond Differently to Common MS Therapy than White People

Retrieved on: 
Friday, April 16, 2021
Neurological disorders, Central nervous system, Autoimmune diseases, Nervous system, Multiple sclerosis, Rare diseases, Central nervous system disorders, Neuromyelitis optica spectrum disorder, Myelitis, Monoclonal antibodies, Balo concentric sclerosis, Inebilizumab

b'MINNEAPOLIS, April 16, 2021 /PRNewswire/ --A preliminary study suggests that Black people who have autoimmune neurologic diseases, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), may respond differently than white people to a common therapy meant to modulate the immune system.

Key Points: 
  • b'MINNEAPOLIS, April 16, 2021 /PRNewswire/ --A preliminary study suggests that Black people who have autoimmune neurologic diseases, multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD), may respond differently than white people to a common therapy meant to modulate the immune system.
  • "We wanted to compare how quickly the B-cells came back in Black people and white people after treatment.
  • "\nThe study involved 168 people, 134 with MS and 32 with neuromyelitis optica spectrumdisorder.
  • The group included 61 who identified as Black and 60 who identified as white.

Noveome Biotherapeutics, Inc. Announces Publication of Preclinical Results Demonstrating the Neuroprotective Properties of Amnion-derived Multipotent Progenitor Cells in Spinal Cord and Retinal Ganglion Cells

Retrieved on: 
Wednesday, October 21, 2020
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Branches of biology, Nervous system, Neuroscience, Central nervous system disorders, Autoimmune diseases, Myelitis, Experimental autoimmune encephalomyelitis, Encephalomyelitis, Neuritis, Nerve, Spinal cord, Optic nerve

These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.

Key Points: 
  • These new, peer-reviewed results demonstrate, for the first time, the neuroprotective properties of systemically delivered AMP cells in mice with experimental autoimmune encephalomyelitis (EAE)-induced experimental optic neuritis (ON) and myelitis.
  • All mice were sacrificed on day 42 post-immunization, and optic nerves and spinal cords were collected for analyses.
  • The hypothesis was that the cells would continue to secrete the secretome in vivo, thus acting like a delivery system.
  • We are pleased to see these preclinical results for the treatment of damaged optic nerves and spinal cord myelitis using systemically administered AMP cells.

Aneurysmal Subarachnoid Hemorrhage (aSAH) Market Insight, Epidemiology and Market Forecasts, 2020-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 8, 2020
Professional services, Consulting, Medical specialties, Organ systems, Clinical medicine, ASAH, Neurosurgery, RTT, Central nervous system disorders, Intensive care medicine, Neurotrauma, Subarachnoid hemorrhage, Aneurysm, SAH, Medical specialties, Organ systems, Clinical medicine, ASAH, Neurosurgery, RTT, Central nervous system disorders, Intensive care medicine, Neurotrauma, Subarachnoid hemorrhage, Aneurysm, SAH, Medical specialties, Organ systems, Clinical medicine, ASAH, Neurosurgery, RTT, Central nervous system disorders, Intensive care medicine, Neurotrauma, Subarachnoid hemorrhage, Aneurysm, SAH

The "Aneurysmal Subarachnoid Hemorrhage (aSAH)- Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Aneurysmal Subarachnoid Hemorrhage (aSAH)- Market Insight, Epidemiology and Market Forecast -2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Aneurysmal Subarachnoid Hemorrhage (aSAH) - Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Aneurysmal Subarachnoid Hemorrhage (aSAH), historical and forecasted epidemiology as well as the Aneurysmal Subarachnoid Hemorrhage (aSAH) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Aneurysmal Subarachnoid Hemorrhage (aSAH) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Aneurysmal Subarachnoid Hemorrhage (aSAH) market size from 2017 to 2030.
  • What was the Aneurysmal Subarachnoid Hemorrhage (aSAH) market share (%) distribution in 2017 and how it would look like in 2030?

Praxis Precision Medicines Announces $110 Million Financing

Retrieved on: 
Tuesday, July 28, 2020
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Central nervous system disorders, Central nervous system disease, Epilepsy, Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Central nervous system disorders, Central nervous system disease, Epilepsy

We are pleased with and excited by this financing, which supports our continued mission to develop best-in-class therapies that deliver long-term value to human health, said Marcio Souza, president and chief executive officer of Praxis.

Key Points: 
  • We are pleased with and excited by this financing, which supports our continued mission to develop best-in-class therapies that deliver long-term value to human health, said Marcio Souza, president and chief executive officer of Praxis.
  • With three programs currently in clinical development for five indications, and additional programs in earlier stages of development, we are making great strides to bring new treatments to patients in the CNS space.
  • Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance.
  • We have established a broad portfolio, including five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes.

AGTC Announces Significant Productivity and Quality Enhancement To Its Proprietary Manufacturing Process

Retrieved on: 
Monday, June 22, 2020
Central nervous system disorders, Otology, Central nervous system disease, Biotechnology

This is in addition to yields that are more than 10-fold higher than what we achieved in our Phase 1/2 manufacturing campaigns.

Key Points: 
  • This is in addition to yields that are more than 10-fold higher than what we achieved in our Phase 1/2 manufacturing campaigns.
  • Dr. Knop and Sue Washer, President and CEO of AGTC, recently authored an article on the challenges of AAV manufacturing at larger scale in the June issue of BioProcess International .
  • AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases.
  • AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

Global Nerve Repair and Regeneration Market (2019 to 2025) - Analysis, Trends, and Forecasts - ResearchAndMarkets.com

Retrieved on: 
Monday, April 27, 2020
Biotechnology, General Health, Health, Physical therapy, Epilepsy, Health, Central nervous system disorders, Epilepsy in animals, Neurological disorder, Central nervous system disease, Medicine, Veterinary medicine

US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth

Key Points: 
  • US and Europe Dominate the Market, Asia-Pacific to Register the Fastest Growth
    High Incidence of Brain Disorders and Nerve Injuries: Primary Market Driver
    EXHIBIT 2: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy
    EXHIBIT 5: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050